SCHEMBL4842559

SCHEMBL4842559

Cc1c(Cl)cnc2[nH]c(-c3ccc(N4CCN(C)CC4)c(N)c3)nc12

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.45
AURKA O14965 2/20 0.41
KDM4E B2RXH2 2/20 0.40
ALDH1A1 P00352 2/20 0.40
MAPT P10636 1/20 0.40
RAD52 P43351 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
HRH4 Q9H3N8 5/20 0.39
WDR5 P61964 3/20 0.38
KMT2A Q03164 2/20 0.38
AXL P30530 1/20 0.38
HSD17B10 Q99714 1/20 0.37
KCNH2 Q12809 2/20 0.37
TERT O14746 1/20 0.36
CDK2 P24941 2/20 0.36
PRKCZ Q05513 2/20 0.36
TNKS O95271 1/20 0.36
PARP1 P09874 1/20 0.36
TNKS2 Q9H2K2 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5256467 0.78 MAPT (0.41) POLBKDM4EALDH1A1MAPTL3MBTL1
SCHEMBL4846517 0.76 GAA (0.39) POLBKDM4EALDH1A1MAPTKMT2A
SCHEMBL4842205 0.74 IKBKE (0.41) POLBKDM4EALDH1A1L3MBTL1KMT2A
SCHEMBL5263227 0.72 IKBKE (0.41) POLBKDM4EALDH1A1L3MBTL1KMT2A
SCHEMBL30361939 0.67 TNKS (0.47) AURKAKDM4EALDH1A1MAPTL3MBTL1
SCHEMBL17289863 0.67 ALK (0.57) KDM4EALDH1A1MAPTHSD17B10KCNH2
SCHEMBL17289825 0.67 TNKS (0.47) AURKAKDM4EALDH1A1MAPTL3MBTL1
SCHEMBL19778609 0.67 JAK2 (0.55) AURKAHRH4KCNH2TNKSPARP1
SCHEMBL30520652 0.67 JAK2 (0.55) AURKAHRH4KCNH2TNKSPARP1
SCHEMBL26986495 0.66 KDM4E (0.54) POLBKDM4EALDH1A1MAPTRAD52

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-100358893-C Certain novel imidazopyridines and uses thereof ASTRAZENECA AB (SE) 2008-01-02 CN claimed
EP-1539759-B1 NOVEL IMIDAZOPYRIDINES AND THEIR USE ASTRAZENECA AB (SE) 2007-08-15 EP claimed
CN-1684964-A Use of and some novel imidazopyridines ASTRAZENECA AB (SE) 2005-10-19 CN claimed
US-7410966-B2 Use of and some novel imidazopyridines ASTRAZENECA AB (SE) 2008-08-12 US disclosed
CN-100358893-C Certain novel imidazopyridines and uses thereof ASTRAZENECA AB (SE) 2008-01-02 CN disclosed
EP-1539759-B1 NOVEL IMIDAZOPYRIDINES AND THEIR USE ASTRAZENECA AB (SE) 2007-08-15 EP disclosed
US-20050261333-A1 Use of and some novel imidazopyridines ASTRAZENECA A B (SE) 2005-11-24 US disclosed
CN-1684964-A Use of and some novel imidazopyridines ASTRAZENECA AB (SE) 2005-10-19 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050261333-A1 Use of and some novel imidazopyridines ITK, CSNK1A1, RPS6KA1 POLB 2858/4885AURKA 512/4885KDM4E 2903/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.